Compare APLD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APLD | PCVX |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 6.0B |
| IPO Year | N/A | 2020 |
| Metric | APLD | PCVX |
|---|---|---|
| Price | $31.32 | $46.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $29.36 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 27.3M | 1.5M |
| Earning Date | 01-13-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,560,000.00 | N/A |
| Revenue This Year | $113.90 | N/A |
| Revenue Next Year | $71.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.43 | N/A |
| 52 Week Low | $3.31 | $27.66 |
| 52 Week High | $40.20 | $94.60 |
| Indicator | APLD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 51.97 |
| Support Level | $26.86 | $43.78 |
| Resistance Level | $30.30 | $48.11 |
| Average True Range (ATR) | 2.52 | 1.99 |
| MACD | 0.92 | -0.49 |
| Stochastic Oscillator | 93.98 | 42.99 |
Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments: Data Center Hosting Business and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business, which operates data centers to provide energized space to crypto mining customers.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.